Last reviewed · How we verify
TRC253
At a glance
| Generic name | TRC253 |
|---|---|
| Also known as | AR Antagonist |
| Sponsor | Tracon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Haematuria
- Musculoskeletal pain
- Pain in extremity
- Anaemia
- Arthralgia
- Blood alkaline phosphatase increased
- Bone Pain
- Cancer pain
- Constipation
- Electrocardiogram QT prolonged
- Fatigue
- Fractured sacrum
Key clinical trials
- Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |